Literature DB >> 28867124

Effect of Nonalcoholic Fatty Liver Disease on In-Hospital and Long-Term Outcomes in Patients With ST-Segment Elevation Myocardial Infarction.

Muhammed Keskin1, Mert İlker Hayıroğlu2, Ahmet Okan Uzun3, Tolga Sinan Güvenç4, Sinan Şahin5, Ömer Kozan2.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is a risk factor for coronary artery disease. We investigated the effect of NAFLD grade on in-hospital and long-term outcomes in patients with ST-segment elevation myocardial infarction (STEMI). The study group consisted of 360 patients with STEMI. The patients were classified according to the grade of the NAFLD using ultrasonography. Based on this classification, all patients were divided into 4 subgroups as grade 0 (no fatty liver disease), grade 1, grade 2, and grade 3. Hierarchical logistic regression and Cox proportional regression analysis were used to establish the relation between NAFLD grade and outcomes. In-hospital mortality for grade 0, 1, 2, and 3 NAFLDs were 4.7%, 8.3%, 11.3%, and 33.9%, respectively. Three-year mortality for grade 0, 1, 2, and 3 NAFLDs were 5.6%, 7.8%, 9.5%, and 33.3%, respectively. In the multivariable hierarchical logistic regression analysis, in-hospital mortality risks were higher for patients with grade 3 NAFLD (odds ratio 4.2). In a multivariable Cox proportional regression analysis, the mortality risk was higher for patients with grade 3 NAFLD (hazard ratio 4.0). In conclusion, in patients with STEMI, the presence of NAFLD is associated with unfavorable clinical outcomes. Among these patients, grade 3 NAFLD had the highest mortality rates. The present study supports NAFLD screening in patients with STEMI.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28867124     DOI: 10.1016/j.amjcard.2017.07.107

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  17 in total

1.  The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease.

Authors:  Mohammed Eslam; Shiv K Sarin; Vincent Wai-Sun Wong; Jian-Gao Fan; Takumi Kawaguchi; Sang Hoon Ahn; Ming-Hua Zheng; Gamal Shiha; Yusuf Yilmaz; Rino Gani; Shahinul Alam; Yock Young Dan; Jia-Horng Kao; Saeed Hamid; Ian Homer Cua; Wah-Kheong Chan; Diana Payawal; Soek-Siam Tan; Tawesak Tanwandee; Leon A Adams; Manoj Kumar; Masao Omata; Jacob George
Journal:  Hepatol Int       Date:  2020-10-01       Impact factor: 6.047

Review 2.  Nonalcoholic Fatty Liver Disease: An Emerging Modern-Day Risk Factor for Cardiovascular Disease.

Authors:  Gashaw Hassen; Abhishek Singh; Gizeshwork Belete; Nidhi Jain; Ivonne De la Hoz; Genesis P Camacho-Leon; Nitsuh K Dargie; Keila G Carrera; Tadesse Alemu; Sharan Jhaveri; Nebiyou Solomon
Journal:  Cureus       Date:  2022-05-30

3.  Cardiovascular Disease in Nonalcoholic Steatohepatitis: Screening and Management.

Authors:  Hersh Shroff; Lisa B VanWagner
Journal:  Curr Hepatol Rep       Date:  2020-06-29

4.  Analysis of Risk Factors for Adverse Cardiovascular Events in Elderly Patients with Acute Myocardial Infarction and Non-Alcoholic Fatty Liver Disease (NAFLD).

Authors:  Wei Xia; Ning Yang; Yuming Li
Journal:  Med Sci Monit       Date:  2020-06-01

Review 5.  Nonalcoholic fatty liver disease and cardiovascular disease phenotypes.

Authors:  Giandomenico Bisaccia; Fabrizio Ricci; Cesare Mantini; Claudio Tana; Gian Luca Romani; Cosima Schiavone; Sabina Gallina
Journal:  SAGE Open Med       Date:  2020-06-20

6.  Impact of Non-Alcoholic Fatty Liver Disease on Cardiovascular Outcomes in Patients With Stable Coronary Artery Disease: A Matched Case-Control Study.

Authors:  Hui-Hui Liu; Ye-Xuan Cao; Di Sun; Jing-Lu Jin; Yuan-Lin Guo; Na-Qiong Wu; Cheng-Gang Zhu; Ying Gao; Qiu-Ting Dong; Xi Zhao; Sha Li; Yan Zhang; Geng Liu; Jian-Jun Li
Journal:  Clin Transl Gastroenterol       Date:  2019-02       Impact factor: 4.488

7.  Nonalcoholic fatty liver disease and mortality from all causes, cardiovascular disease, and cancer: a meta-analysis.

Authors:  Yan Liu; Guo-Chao Zhong; Hao-Yang Tan; Fa-Bao Hao; Jie-Jun Hu
Journal:  Sci Rep       Date:  2019-07-31       Impact factor: 4.379

8.  Nonalcoholic fatty liver disease, a potential risk factor of non-specific ST-T segment changes: data from a cross-sectional study.

Authors:  Li Xiao; Tao Bai; Junchao Zeng; Rui Yang; Ling Yang
Journal:  PeerJ       Date:  2020-05-13       Impact factor: 2.984

Review 9.  NAFLD and cardiovascular diseases: a clinical review.

Authors:  Philipp Kasper; Anna Martin; Sonja Lang; Fabian Kütting; Tobias Goeser; Münevver Demir; Hans-Michael Steffen
Journal:  Clin Res Cardiol       Date:  2020-07-21       Impact factor: 5.460

Review 10.  Relationship between non-alcoholic fatty liver disease and coronary heart disease.

Authors:  Ugur Arslan; Mustafa Yenerçağ
Journal:  World J Clin Cases       Date:  2020-10-26       Impact factor: 1.337

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.